President Donald Trump introduced TrumpRx.gov, a new federal drug-pricing website aimed at helping Americans find lower prices for prescription medicines amid broader concerns about health care costs. Trump said the site will give consumers access to reduced drug prices through manufacturer links and pharmacy coupons.

The move comes as the Trump administration has been criticized for spiraling health care costs after the expiration of Obamacare insurance subsidies.

“You’re going to save a fortune,” Trump said at the site’s rollout event at the White House. “And this is also so good for overall health care.”

TrumpRx does not function as an online pharmacy. Instead, the government-operated portal directs users with valid prescriptions to drugmakers’ direct-to-consumer websites or provides coupons that can be presented at participating pharmacies. The site launched with over 40 discounted brand-name medications, including popular weight-loss drugs like Ozempic and Wegovy, as well as treatments for diabetes, asthma and fertility.

The platform is tied to agreements the administration negotiated with major pharmaceutical companies under its so-called “most-favored nation” pricing strategy, which seeks to align U.S. drug prices with the lowest prices paid in other developed countries.

Administration officials has hailed the launch as an important step in addressing high out-of-pocket drug costs, particularly for uninsured Americans. Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz joined Trump at the unveiling, offering enthusiastic support for the effort.

But some health policy analysts and consumer advocates say the benefits for Americans with private insurance are likely to be modest to small. Juliette Cubanski, deputy director for Medicare policy at the Kaiser Family Foundation, noted that many individuals with coverage may already have lower prices through their insurance plans. “There is a real question about the value of this for people with insurance,” she said.

Critics also point out that many of the branded medications listed on TrumpRx have cheaper generic alternatives available elsewhere or lower costs through existing insurer networks. Experts say the portal may function more as a coupon directory than a solution to systemic price issues.

The administration has emphasized that it expects additional drugs and manufacturers to join the platform over time. Currently, several major companies, including Pfizer, Novo Nordisk, Eli Lilly, AstraZeneca and EMD Serono, have pricing arrangements that contributed to the initial list of launch medications.

Supporters of TrumpRx say uninsured and underinsured patients who pay cash for prescriptions could see meaningful savings. Opponents argue that insured consumers will derive limited benefit and may forgo coverage advantages, such as insurance deductibles and co-pays, for out-of-pocket costs that do not count toward their annual limits